斯坦福神经调节疗法治疗难治性抑郁症：一项系统评价。
Stanford neuromodulation therapy for treatment-resistant depression: a systematic review.
作者信息
Lan Xian-Jun, Cai Dong-Bin, Liu Qi-Man, Qin Zhen-Juan, Pridmore Saxby, Zheng Wei, Xiang Yu-Tao
机构信息
The Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China.
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
出版信息
Front Psychiatry. 2023 Dec 13;14:1290364. doi: 10.3389/fpsyt.2023.1290364. eCollection 2023.
OBJECTIVE
This systematic review of randomized controlled studies (RCTs) and observational studies evaluated the efficacy and safety of stanford neuromodulation therapy (SNT) for patients with treatment-resistant depression (TRD).
METHODS
A systematic search (up to 25 September, 2023) of RCTs and single-arm prospective studies was conducted.
RESULTS
One RCT ( = 29) and three single-arm prospective studies ( = 34) met the study entry criteria. In the RCT, compared to sham, active SNT was significantly associated with higher rates of antidepressant response (71.4% versus 13.3%) and remission (57.1% versus 0%). Two out of the three single-arm prospective studies reported the percentage of antidepressant response after completing SNT, ranging from 83.3% (5/6) to 90.5% (19/21). In the three single-arm prospective studies, the antidepressant remission rates ranged from 66.7% (4/6) to 90.5% (19/21). No severe adverse events occurred in all the four studies.
CONCLUSION
This systematic review found SNT significantly improved depressive symptoms in patients with TRD within 5 days, without severe adverse events.
目的
本项对随机对照研究（RCT）和观察性研究的系统评价评估了斯坦福神经调节疗法（SNT）治疗难治性抑郁症（TRD）患者的疗效和安全性。
方法
对RCT和单臂前瞻性研究进行了系统检索（截至2023年9月25日）。
结果
一项RCT（n = 29）和三项单臂前瞻性研究（n = 34）符合研究纳入标准。在RCT中，与假手术组相比，活性SNT与更高的抗抑郁反应率（71.4%对13.3%）和缓解率（57.1%对0%）显著相关。三项单臂前瞻性研究中有两项报告了完成SNT后的抗抑郁反应百分比，范围从83.3%（5/6）到90.5%（19/21）。在三项单臂前瞻性研究中，抗抑郁缓解率范围从66.7%（4/6）到90.5%（19/21）。所有四项研究中均未发生严重不良事件。
结论
本系统评价发现，SNT可在5天内显著改善TRD患者的抑郁症状，且无严重不良事件。
Zotero 插件